Research output

Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene

Research output: Contribution to journalArticleAcademicpeer-review

Associated researcher

  • Blommestein, H. M.
  • Armstrong, N.
  • Ryder, S.
  • Deshpande, S.
  • Worthy, G.
  • Noake, C.
  • Riemsma, R.
  • Kleijnen, J.M.P.

  • Severens, J. L.
  • Al, M. J.

Associated organisations

    Research areas

  • LENALIDOMIDE, Best Suoortive Care, Evidence Review Group, Acute Myeloid Leukemia, Appraisal Committee
View graph of relations

Details

Original languageEnglish
Pages (from-to)23-31
Number of pages9
JournalPharmacoeconomics
Volume34
Issue number1
DOIs
Publication statusPublished - Jan 2016